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molecular biology ofnasopharyngeal carcinoma
Held at the Paterson Institutefor Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.
18-21 October 1987
Organisers: J.R. Arrand, M. Mackett & E. Littler
The association of Epstein-Barr Virus (EBV) with the
malignant epithelial cells of undifferentiated nasopharyngeal
carcinoma is well recognised. What is not so clear is the
precise role, if any, of the virus in the establishment and
maintenance of this disease and how various cofactors may
interact with EBV to bring about the onset of the neoplasm.
This meeting reviewed the current state of our understanding
of some of the molecular biological processes relevant to the
genesis, diagnosis and prevention of a cancer which afflicts
several thousand people per year in southeast Asia and many
others worldwide.
Carcinogenesis is currently thought to be a multifactorial
process and the virologists' enthusiasm was tempered by
some epidemiological insights into the potential involvement
of other agents. Nick Day (Cambridge) showed that a
significant genetic predisposition to NPC is related to certain
HLA types, in particular A2, B17, and BW46. Interestingly
the last appears to be present only in Chinese populations.
Guy de The (Lyon) pointed out that ethnic differences in
similar geographical regions (eg Southern China) are
associated with marked variations in the frequency of NPC
and that these could be attributable to differences in food
habits. Relatively high levels of nitrosamines and mutagens
are found in some of the staple foods of high risk areas.
Extracts from Chinese dried salted fish or some traditional
food from Tunisia (another high risk area) act like the
phorbol ester TPA to activate the latent EBV in Raji cells in
tissue culture. Hans Wolf (Munich) showed results obtained
by Yi Zeng (Beijing) demonstrating similar activation by
extracts from several traditional Chinese medicinal herbs.
Over the past few years, a great deal of attention has been
devoted to the association of cellular oncogenes with various
cancers, but NPC has been conspicuously absent from most
studies. Jin-Quan Jiang (Shanghai) presented data which
showed that DNA extracted from NPC biopsies could be
transfected into NIH 3T3 cells and cause cellular trans-
formation. The transformants contained the human H-ras
oncogene and would form tumours when injected into nude
mice but they did not contain any EBV DNA. Since thefgr
oncogene appears to be elevated in EBV-associated Burkitt's
lymphoma, Nancy Raab-Traub (North Carolina) examined
NPC biopsies and nude mouse-passaged cells for this gene
but failed to find any association. However, the myc gene
was found to be elevated in a liver metastasis from a
primary NPC. Clearly the role, if any, of cellular oncogenes
involved with NPC needs a good deal more attention.
Beverly Griffin (London) described further transfection
experiments in which large segments of EBV DNA were
shown to immortalize primary epithelial cells from African
Green Monkey, Common Marmoset or Human. The EBV
DNA used for transfection was present in the cells early
after immortalization but after continued passage most was
lost. At late passage the remaining EBV DNA was present at
very low copy number and appeared to be randomly
integrated into the host DNA. It is interesting that the
region of the virus genome which produces this effect
includes the genes for the major DNA binding protein, DNA
polymerase, thymidine kinase and glycoprotein B equivalent.
This region of EBV is homologous to that of Herpes simplex
virus and in the latter case there have been reports that this
region may cause morphological transformation in rodent
cells. The mechanism of such transformation by HSV is a
notoriously confusing and contentious issue. These
experiments hint that EBV research may be heading in the
same direction. It is noteworthy that some of the 'early'
RNA species identified by others in NPC biopsies (see
below) map in this part of the EBV genome.
Until fairly recently EBV was considered to be exclusively
a B-lymphotropic herpes virus and the observed presence of
EBV within the epithelial cells of NPC was something of
an embarrassment. John Sixby (Memphis) provided an
explanation by showing very clear immuno-electronmicro-
scopic data which demonstrated EBV receptors on and virus
binding to the surface of epithelial cells. Wolf supports the
concept of the parotid gland as a site for replication of EBV.
Other workers have failed to detect EBV in this tissue
although Raab-Traub has detected the virus in a parotid
carcinoma. Beda Brichacek (Prague) reported on the
presence of EBV in both tonsillar and supraglottic
carcinomas whilst some time ago Maria Lung (Hong Kong)
reported that EBV could be found in the lower respiratory
tract. The virus thus seems to be more widely distributed
than was for long suspected. However, these reported
'sightings' are somewhat sporadic and it remains to be seen
what the frequency of residence in different tissues associated
with the respiratory tract will turn out to be.
The question of EBV gene expression in NPC or nude
mouse passaged tumour cells was addressed by several
speakers. There was a general consensus that very little, if
any, detectable late gene expression occurs in the samples.
Anne Goodeve (Manchester) and Lung presented evidence
using Southern blotting and immunostaining respectively, for
the presence of EBV in nasopharyngeal tissue from normal
seropositive individuals. Unfortunately, due to the difficulty
of obtaining suitable samples, no data are yet available from
control experiments on biopsies from normal seronegatives.
In contrast to the foregoing, Bengt Kallin (Stockholm) found
no evidence for EBV being present in normal naso-
pharyngeal tissue. This discrepancy must be resolved.
In EBV positive lymphoid cell lines the number of latent
nuclear proteins (Epstein-Barr Virus Nuclear Antigens,
EBNAs) has been steadily increasing. However Lawrence
Young (Birmingham) and Kallin agreed that in NPC biopsies
only EBNA 1 was detectable by Western blotting, along with
the latent membrane protein, (LMP). At the RNA level,
Goodeve, Raab-Traub and Martin Allday (London) agreed
that EBV specific transcription was more complex than in
latently infected B-lymphocytes and probably includes some
'early' transcripts. The results were not in complete accord,
possibly due to various experimental approaches to the
problem. Experiments are needed to identify in NPC biopsies
the presence of EBV encoded polypeptides predicted by the
RNA data.
The importance of early diagnosis in terms of patient
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survival was emphasised by de The, Wolf and Mei Ying Liu
(Taipei). The diagnostic value of elevated IgA antibodies
against EBV early antigen and virus capsid antigen was
discussed by the first two speakers whilst Liu showed more
specifically that antibodies against the EBV DNase had a
predictive value in diagnosing NPC.
The need for a vaccine against EBV as a means of
preventing NPC was introduced by Anthony Epstein (Oxford)
and was followed by descriptions of the progress towards
this goal. The use of the EBV glycoprotein gp340 which will
induce EBV-neutralising antibodies was chronicled by
Andrew Morgan (Bristol). Using the cottontop tamarin as an
experimental model encouraging results have been obtained
by presenting this glycoprotein to the animals using
ISCOMS, with a muramyl dipeptide or expressed in a
vaccinia virus recombinant. Ling Chan (London) described
how the EBV homologue of the HSV glycoprotein B may be
useful as a basis for a vaccine whilst Mike Mackett
(Manchester) suggested that other predicted EBV glyco-
protein genes incorporated into vaccinia virus either alone or
in concert with gp340 may be useful.
Many people felt that a vaccine against EBV should, if it
is to be effective against NPC, prevent primary infection and
establishment of latency by the virus possibly by stimulating
anti-EBV IgA. In the experiments on prevention of EBV-
induced lymphoma development in cottontop tamarins it
was not clear whether these desiderata had been obtained.
Nina Wedderburn (London) showed that common marmosets
could be infected orally by EBV and exhibited serum
responses similar to that seen in humans suffering from
infectious mononucleosis. Thus this animal may be an
appropriate model to use as a test for prevention of primary
infection.
Alan Rickinson (Birmingham) pointed out that knowledge
of the immunology of the normal EBV infection was rather
primitive and suggested that an effective vaccine may require
the generation of cytotoxic T cells directed against processed
forms of EBV latent proteins. David Tyrrell (Salisbury)
reviewed the vaccine field and felt there is reason for
cautious optimism that a vaccine will succeed but clearly
much remains to be understood both on the genesis of NPC
and as to how to deliver the appropriate antigens.
The symposium was supported by a grant from the General
Research Endowment Fund of the Christie Hospital.